Association between percutaneous coronary intervention and long-term C-reactive protein levels in patients with acute coronary syndromes

Kausik K. Ray, Babak Nazer, Richard Cairns, C. Michael Gibson, Christopher P. Cannon

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

C-reactive protein (CRP) is an independent predictor of risk in ACS patients, and it has been previously shown that percutaneous coronary intervention (PCI) is associated with an early rise in CRP. To assess the long-term relationship between PCI and CRP, we compared CRP levels at baseline, 30 days, 4 months and 24 months among patients in the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 trial who were treated with PCI and those who did not receive PCI. At study entry, CRP was significantly higher among patients who had undergone PCI (13.2 vs. 9.5 mg/l, P < 0.001). However, by day 30 CRP was significantly lower among patients who had undergone PCI for management of the index event (1.5 vs. 2.1 mg/l, P < 0.001) and remained lower at 4 months and by end of study (average 2 years after ACS). Using a multivariable model, we observed that PCI was associated with 8.6% lower CRP level at month 4 (P = 0.05) and 14.2% at approximately 2 years (P = 0.0028). These analyses suggest that although PCI may acutely increase inflammation, it may also serve a role in decreasing inflammation associated with atherosclerotic plaques via long-term mechanical stabilization.

Original languageEnglish (US)
Pages (from-to)10-13
Number of pages4
JournalJournal of Thrombosis and Thrombolysis
Volume30
Issue number1
DOIs
StatePublished - Jul 2010
Externally publishedYes

Fingerprint

Percutaneous Coronary Intervention
Acute Coronary Syndrome
C-Reactive Protein
Inflammation
Pravastatin
Atherosclerotic Plaques
Protein C
Myocardial Infarction
Infection

Keywords

  • Acute coronary syndromes
  • C-reactive protein
  • Inflammation
  • Percutaneous coronary intervention

ASJC Scopus subject areas

  • Hematology
  • Cardiology and Cardiovascular Medicine
  • Medicine(all)

Cite this

Association between percutaneous coronary intervention and long-term C-reactive protein levels in patients with acute coronary syndromes. / Ray, Kausik K.; Nazer, Babak; Cairns, Richard; Michael Gibson, C.; Cannon, Christopher P.

In: Journal of Thrombosis and Thrombolysis, Vol. 30, No. 1, 07.2010, p. 10-13.

Research output: Contribution to journalArticle

@article{1435b11167b141eab1a3c2b81f9a85f7,
title = "Association between percutaneous coronary intervention and long-term C-reactive protein levels in patients with acute coronary syndromes",
abstract = "C-reactive protein (CRP) is an independent predictor of risk in ACS patients, and it has been previously shown that percutaneous coronary intervention (PCI) is associated with an early rise in CRP. To assess the long-term relationship between PCI and CRP, we compared CRP levels at baseline, 30 days, 4 months and 24 months among patients in the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 trial who were treated with PCI and those who did not receive PCI. At study entry, CRP was significantly higher among patients who had undergone PCI (13.2 vs. 9.5 mg/l, P < 0.001). However, by day 30 CRP was significantly lower among patients who had undergone PCI for management of the index event (1.5 vs. 2.1 mg/l, P < 0.001) and remained lower at 4 months and by end of study (average 2 years after ACS). Using a multivariable model, we observed that PCI was associated with 8.6{\%} lower CRP level at month 4 (P = 0.05) and 14.2{\%} at approximately 2 years (P = 0.0028). These analyses suggest that although PCI may acutely increase inflammation, it may also serve a role in decreasing inflammation associated with atherosclerotic plaques via long-term mechanical stabilization.",
keywords = "Acute coronary syndromes, C-reactive protein, Inflammation, Percutaneous coronary intervention",
author = "Ray, {Kausik K.} and Babak Nazer and Richard Cairns and {Michael Gibson}, C. and Cannon, {Christopher P.}",
year = "2010",
month = "7",
doi = "10.1007/s11239-010-0463-7",
language = "English (US)",
volume = "30",
pages = "10--13",
journal = "Journal of Thrombosis and Thrombolysis",
issn = "0929-5305",
publisher = "Springer Netherlands",
number = "1",

}

TY - JOUR

T1 - Association between percutaneous coronary intervention and long-term C-reactive protein levels in patients with acute coronary syndromes

AU - Ray, Kausik K.

AU - Nazer, Babak

AU - Cairns, Richard

AU - Michael Gibson, C.

AU - Cannon, Christopher P.

PY - 2010/7

Y1 - 2010/7

N2 - C-reactive protein (CRP) is an independent predictor of risk in ACS patients, and it has been previously shown that percutaneous coronary intervention (PCI) is associated with an early rise in CRP. To assess the long-term relationship between PCI and CRP, we compared CRP levels at baseline, 30 days, 4 months and 24 months among patients in the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 trial who were treated with PCI and those who did not receive PCI. At study entry, CRP was significantly higher among patients who had undergone PCI (13.2 vs. 9.5 mg/l, P < 0.001). However, by day 30 CRP was significantly lower among patients who had undergone PCI for management of the index event (1.5 vs. 2.1 mg/l, P < 0.001) and remained lower at 4 months and by end of study (average 2 years after ACS). Using a multivariable model, we observed that PCI was associated with 8.6% lower CRP level at month 4 (P = 0.05) and 14.2% at approximately 2 years (P = 0.0028). These analyses suggest that although PCI may acutely increase inflammation, it may also serve a role in decreasing inflammation associated with atherosclerotic plaques via long-term mechanical stabilization.

AB - C-reactive protein (CRP) is an independent predictor of risk in ACS patients, and it has been previously shown that percutaneous coronary intervention (PCI) is associated with an early rise in CRP. To assess the long-term relationship between PCI and CRP, we compared CRP levels at baseline, 30 days, 4 months and 24 months among patients in the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 trial who were treated with PCI and those who did not receive PCI. At study entry, CRP was significantly higher among patients who had undergone PCI (13.2 vs. 9.5 mg/l, P < 0.001). However, by day 30 CRP was significantly lower among patients who had undergone PCI for management of the index event (1.5 vs. 2.1 mg/l, P < 0.001) and remained lower at 4 months and by end of study (average 2 years after ACS). Using a multivariable model, we observed that PCI was associated with 8.6% lower CRP level at month 4 (P = 0.05) and 14.2% at approximately 2 years (P = 0.0028). These analyses suggest that although PCI may acutely increase inflammation, it may also serve a role in decreasing inflammation associated with atherosclerotic plaques via long-term mechanical stabilization.

KW - Acute coronary syndromes

KW - C-reactive protein

KW - Inflammation

KW - Percutaneous coronary intervention

UR - http://www.scopus.com/inward/record.url?scp=77953872891&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953872891&partnerID=8YFLogxK

U2 - 10.1007/s11239-010-0463-7

DO - 10.1007/s11239-010-0463-7

M3 - Article

VL - 30

SP - 10

EP - 13

JO - Journal of Thrombosis and Thrombolysis

JF - Journal of Thrombosis and Thrombolysis

SN - 0929-5305

IS - 1

ER -